Alam M N, Haq S A, Das K K, Baral P K, Mazid M N, Siddique R U, Rahman K M, Hasan Z, Khan M A, Dutta P
Department of Medicine, Institute of Postgraduate Medicine and Research, Dhaka, Bangladesh.
Am J Trop Med Hyg. 1995 Sep;53(3):306-11. doi: 10.4269/ajtmh.1995.53.306.
The efficacy of two regimens of ciprofloxacin was compared in a randomized study conducted on 69 patients with enteric fever, 52.2% of whom had infection with multidrug-resistant (MDR) strains of Salmonella typhi or S. paratyphi. Patients were randomly assigned to two regimens (10 days versus 14 days) of ciprofloxacin (500 mg twice a day). The mean +/- SD time required for defervescence was similar for both regimens (4.2 +/- 1.9 days in the 10-day group and 4.9 +/- 2.6 days in the 14-day group). A 100% cure was observed in each treatment group and no serious side effects were observed. Relapse occurred in two patients (14-day regimen). Only one patient (14-day regimen) had growth of S. typhi in stool culture at the time of the first follow-up three days after completion of therapy. Follow-up studies on available patients on two, six, and 12 months after completion of therapy revealed that all patients had negative stool cultures for S. typhi and S. paratyphi. This study indicates that ciprofloxacin may be recommended as an initial therapy for enteric fever for adult men and nonpregnant and nonlactating women in areas where MDR strains of S. typhi and S. paratyphi are prevalent, and that 500 mg twice a day of the drug given for 10 days is as effective as 14 days at the same dosage.
在一项针对69例肠热症患者开展的随机研究中，比较了两种环丙沙星治疗方案的疗效，其中52.2%的患者感染了多重耐药（MDR）的伤寒沙门菌或副伤寒沙门菌。患者被随机分配至两种环丙沙星治疗方案（10天与14天），剂量均为每日两次，每次500mg。两种治疗方案退热所需的平均±标准差时间相似（10天治疗组为4.2±1.9天，14天治疗组为4.9±2.6天）。每个治疗组的治愈率均为100%，且未观察到严重副作用。两名患者（14天治疗方案组）出现复发。在治疗完成后三天的首次随访时，仅一名患者（14天治疗方案组）的粪便培养中有伤寒沙门菌生长。对完成治疗的患者在治疗完成后的2个月、6个月和12个月进行的随访研究显示，所有患者的粪便培养中伤寒沙门菌和副伤寒沙门菌均为阴性。本研究表明，在伤寒沙门菌和副伤寒沙门菌多重耐药菌株流行的地区，环丙沙星可推荐作为成年男性以及非妊娠和非哺乳期女性肠热症的初始治疗药物，且每日两次、每次500mg的药物服用10天与相同剂量服用14天的疗效相同。
